Individualized Anticoagulant Therapy for Warfarin in a Patient with Poor Metabolism

doi:10.19803/j.1672-8629.2020.12.20

Abstract

Abstract: Objective To investigate the role of clinical pharmacists in individualized anticoagulation therapy of warfarin.Methods The clinical pharmacist participated in the individualized anticoagulant treatment of warfarin in one patient. According to the guidelines, the clinical pharmacist recommend discontinuing aspirin and using warfarin monotherapy. The dose of warfarin was adjusted according to the genetic test results, the prothrombin time, INR and the occurrence of bleeding events and other pharmaceutical monitoring datas were followed.Results The doctor accepted the advice of clinical pharmacists, discontinued aspirin and warfarin 1.25mg/d was applied. The detection results were within the target range, no bleeding and embolic events occurred.Conclusion Clinical pharmacists guide individualized administration of warfarin through genetic testing to ensure the safety and effectiveness of medication for patients and realize the whole-process, individualization and optimization of anticoagulation therapy.

Key words: CYP2C9 and VKORC1 genes, warfarin, individualization, anticoagulation, pharmaceutical care

CLC Number:

R973R969.3

LI Yu, FAN Huihui, FENG Xiaojun, WANG Yunhong, CHEN Chuantao, ZHANG Lei. Individualized Anticoagulant Therapy for Warfarin in a Patient with Poor Metabolism[J]. Chinese Journal of Pharmacovigilance, 2020, 17(12): 939-942.

Add to citation manager EndNote|Ris|BibTeX

URL: https://www.zgywjj.com/EN/10.19803/j.1672-8629.2020.12.20

https://www.zgywjj.com/EN/Y2020/V17/I12/939

References

[1] Go AS,Hylek EM,Phillips KA,et al.Prevalence of diagnosed atrial fibrillation in adults:national implications for rhythm management and stroke prevention:the Anticoagulation and Risk Factors in Atrial Fibrillation (ATRIA) Study[J].JAMA,2001,85(18):2370-2375.
[2] Yi X,Lin J,Han Z,et al.Preceding Antithrombotic Treatment Is Associated with Acute Ischemic Stroke Severity and Functional Outcome at 90 Days among Patients with Atrial Fibrillation[J].J Stroke Cerebrovasc Dis,2019,28(7):2003-2010.
[3] Chinese Society of Cardiology,Committee of Cardio-Cerebral-Vascular Diseases of Gerontological Society of China.Chinese Expert Consensus on Warfarin Anticoagulation Therapy[J].Chinese Journal of Internal Medicine(中华内科杂志),2013,52(1):76-82.
[4] Zhang S,Yang YM,Huang CX,et al.Guideline of stroke prevention in Chinese patients with atrial fibrillation(2017)[J].Chinese Journal of Cardiac Arrhythmias(中华心律失常学杂志),2018,22(1):17-30.
[5] Peng J,Tan SL,Zhou HH,et al.Pharmacogenomics of warfarin and its personalized treatment[J].Chinese Pharmacological Bulletin(中国药理学通报),2013,29(2):169-172.
[6] Wang TY.Effectively Initiating and Maintaining Anticoagulation in Patients with Atrial Fibrillation[J].Circulation,2019,139(15):1763-1765.
[7] Lévy S,Maarek M,Coumel P,et al.Characterization of different subsets of atrial fibrillation in general practice in France:the ALFA study.The College of French Cardiologists[J].Circulation,1999,99(23):3028-3035.
[8] Siu CW,Tse HF.Net clinical benefit of warfarin therapy in elderly Chinese patients with atrial fibrillation[J].Circ Arrhythm Electrophysiol,2014,7(2):300-306.
[9] Li Z,Zhang DF,Zou M,et al.The effect of whole-course pharmaceutical monitoring on anticoagulant therapy in patients with atrial fibrillation[J].Chinese Journal of Hospital Pharmacy(中国医院药学杂志),2019,39(6):628-631.
[10] Hou KL,Yang YH,Wang ZH,et al.Effectiveness of Pharmacist-Participated Warfarin Anticoagulation Management on Patients with Pulmonary Embolism[J].Chinese Pharmaceutical Journal(中国药学杂志),2018,53(8):646-651.
[11] Yin T,Miyata T.Warfarin dose and the pharmacogenomics of CYP2C9 and VKORC1 - rationale and perspectives[J].Thromb Res,2007,120(1):1-10.
[12] Lou Y,Liu H,Han LL,et al.Influence of CYP2C9 and VKORC1 Genetic Polymorphisms on Maintenance Warfarin Dose in Chinese Pulmonary Embolism Patients[J].Chinese Journal of Pharmacovigilance(中国药物警戒),2012,9(4):202-204.
[13] Syn NL,Wong AL,Lee SC,et al.Genotype-guided versus traditional clinical dosing of warfarin in patients of Asian ancestry:a randomized controlled trial[J].BMC Med,2018,16(1):104.
[14] Biswas M,Bendkhale SR,Deshpande SP,et al.Association between genetic polymorphisms of CYP2C9 and VKORC1 and safety and efficacy of warfarin:Results of a 5 years audit[J].Indian Heart J,2018,70(Suppl 3):S13-S19.
[15] Hosseinkhani Z,Sadeghalvad M,Norooznezhad F,et al.The effect of CYP2C9*2,CYP2C9*3,and VKORC1-1639 G>A polymorphism in patients under warfarin therapy in city of Kermanshah[J].Res Pharm Sci,2018,13(4):377-384.
[16] Wang KL,Lip GY,Lin SJ,et al.Non-Vitamin K Antagonist Oral Anticoagulants for Stroke Prevention in Asian Patients With Nonvalvular Atrial Fibrillation:Meta-Analysis[J].Stroke,2015,46(9):2555-2561.
[17] Abraham NS,Singh S,Alexander GC,et al.Comparative risk of gastrointestinal bleeding with dabigatran,rivaroxaban,and warfarin:population based cohort study[J].BMJ,2015(350):h1857.